Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer

Paul A. Bunn, F. Anthony Greco, Lawrence Einhorn

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

The discovery that etopside is one of the most active drugs in small-cell lung cancer (SCLC) led to its incorporation into a number of first-line combination chemotherapy regimens. The cyclophosphamide/ doxorubicin/etoposide (CAE) regimen was shown to be as active or more active than other standard regimens in nonrandomized studies. In a randomized study presented in this report, the CAE regimen was significantly superior to the cyclophosphamide/doxorubicin/vincristine (CAV) regimen for response duration and survival in extensive-stage patients. In limited-stage patients the results were slightly better with CAE. In addition, CAE lacked the neurotoxicity of CAV.

Original languageEnglish (US)
Pages (from-to)45-53
Number of pages9
JournalSeminars in oncology
Volume13
Issue number3 SUPPL. 3
StatePublished - Sep 1986

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this